 Abstract-Huntington's disease is a hereditary neurodegenerative disease in which a few cell types in the sub-cortical brains undergo selective degeneration leading to neurological and cognitive decline and death. The disease is caused by expanded CAG repeat within the first exon of the Huntington gene (HTT). However, the mechanisms of molecular pathogenesis of this disease are not well understood. There is currently no therapy or a cure. We used a model of the disease in the simple organism Saccharomyces cerevisiae that previous workers in the field had successfully utilized to determine putative molecular mechanisms related to the disease. Using this model, we identified 41 novel genes that appear to suppress the toxic effects of the mutant genes. We generated a network of physical and genetic interactions among the human homologs of these novel suppressor genes, and analysis of this network allowed us to propose for the first time that mRNA degradation mechanisms might be affected in the diseased cells.
I. INTRODUCTION
Brain disorders, especially neurodegenerative diseases, represent an enormous disease burden, in terms of human suffering and economic cost [1] .Many brain disorders are chronic and even incurable,whose disabling effects may continue for years or even decades. Huntington's disease (HD) is a dominantly inherited neurodegenerative disease diagnosed by excessive repeats of the CAG codon within the first exon of theHuntingtin(HTT)diseasegene [2] , [3] .The codon CAG translates to the amino acid glutamine (Q) in the corresponding Httprotein [2] , [3] . More than 36successive glutamine residues within this region of the HTT protein induce a toxic gain of function in certain specific brain cells (e.g. spiny neurons of the striatum) leading to abnormal electrical and neurochemical functions, and eventuallyto premature death [4] . The early symptoms of Huntington's disease include: motor dysfunction, cognitive decline,involuntary muscle movement and progressive dementia. Later, many additional brain cell types also undergo premature degeneration, and ultimately these events lead to death of the patients. The disease affects an estimated 3 to 7 per 100,000 people of European ancestry. In the United States alone, about 30,000 people have Huntington's disease; estimates of its prevalence are approximately 1 in every 10,000 people and an additional 70,000 people are at risk. The common and rare neurodegenerative diseases, including Huntington's disease,share the same trinucleotide CAG expansion related mechanism of pathogenesis [5] , andthese diseases are together called poly-Q (or CAG-repeat, by their coding sequences)domain containing diseases. The abnormal CAG expansion in HD results in conformational changes andincreased nuclear accumulation of mutant htt protein.
The misfoldingand aggregation of this abnormal protein is widely believed to exert cytoxicity in the brain cells. Previous findings on pathogenic role of aggregates and soluble forms of mutant httare contradictory and are highly debated, and the exact molecular and cellular mechanisms of HD pathogenesis still remain elusive.
Research on Huntington's disease is currently focused on understandingthe molecular basis of the cellular degeneration phenotype [3] , [5] . Several cellular and genetic studies have been conducted in model systems, such as the yeast Saccharomyces cerevisiae,whichharbor the mutant form of the human HTT gene fragment containing high poly-Q repeats, under conditions that either enhance or reduce the level of toxicity [3] . Previous approaches towards toxicity suppression have involved screening of yeast strains with systematic gene deletion mutations, to identify specific suppressor mutations that alleviate the effect of the mutant htt toxic fragment (Htt103Q),yet have no effect in the same yeast strains expressing the normal HTT fragment (Htt25Q) [2] . This genome-wide loss of function screens in yeast along with functional gene expression profiling studies have revealed several genes that can suppress the toxic effects of Htt103Q. These toxicity suppressors genes are mostly enrichedin rRNA processing and ribosome biogenesis related genes [3] . Though the mechanisms by which deletion of certain ribosomal protein genes would suppress the toxic effects of Htt103Q havenot been deciphered yet, nucleolar stress signaling mechanismsvia ribosomal RNA transcription dysfunction have recently been implicated in HD [6] , [7] .
In a previous genome-wide screen [2] , gene deletions were identified as the suppressors of mutant Htt toxicity. One such mutation known as bna4,in the gene that encodes the enzyme kynureninemonoxygenase (KMO), led to drastically reduced amounts of two metabolites, 3-hydroxykynurenine (3-HK) and quinolinic acid (QUIN) involved in the biosynthetic pathway of nicotinamide adenine dinucleotide (NAD) from tryptophan and this also simultaneously suppressed the cellular toxicity of Htt103Q in a HD mouse model. Therefore one objective in certain HD models was to inhibit the expression of these two metabolites for therapeutic purposes. In fact, inhibition of the biosynthesis of these metabolites in human HD patients is currently under way in clinical trials [5] .
Another study [3] involved an oligonucleotide microarray experiment with these deletion-mutant suppressors of toxicity for identifying genes that were upregulated or down-regulated (differentially expressed genes, DEGs) when Htt103Q fragment was expressed in yeast. Gene expression profiling and network analysis of these DEGs in the three suppressor strains [bna4, ume1, and mbf1 mutants, respectively] in terms of gene ontology (GO) enrichment led to the finding that the DEGs are relevant to the processes of ribosomal biogenesis, rRNA processing, and protein biogenesis. Ribosomal dysfunction has also been implicated in neuronal apoptosis [8] . Downregulation of ribosomal RNA (rRNA) results in the accumulation of unassembled free ribosomal proteins such as RpL5, RpL11 and RpL23, thereby eliciting a cascade of nucleolar stress signaling for neuronal death in polyQ patients and other disease models [6] . Though dysfunctional ribosome biogenesis and nucleolar stress are considered some of the pathogenic mechanisms, it is widely believed that in the absence of a deeper understanding of the biology of mutant Htt proteins, it will be difficult to find an appropriate drug for humans. One reason for this belief is the wide variation in the age of onset of HD in humans having the same or similar lengths of the poly-Q repeat in Htt, suggesting the existence of genetic modulators of Htt toxicity which vary among individuals. To better understand this process, simpler model systems including yeast are currently being pursued to identify the modulators of mutant htt toxicity using genetic and protein interaction networks that contains ribosomes and other associated proteins.
Here we report for the first time, the systematic screening of 243 ribosomal protein genes that can suppress the toxic effects of Htt103Q in yeast, when over-expressed (as opposed to deletion mutations in ribosomal genes in previous studies). Through this screen we have identified 41 genes that, when over-expressed, suppressed Htt103Q toxicity. Most of these suppressor genes have human homologs, and we have constructed an interaction network of human genes starting from this set of homologous genes, which should be important for further understanding of the molecular basis of Huntington's disease pathogenesis.
II. RESEARCH GOALS AND QUESTIONS
Encouraged by the previous experiments yielding genes as toxicity suppressors, we asked the following research questions:
1) "Can other ribosomal genes suppress cellular toxicity of Htt103Q when overexpressed?" 2) "Can the understanding of how these genes suppress toxicity lead to a mechanism for better understanding Htt103Q toxicity in brain cells?" 
III. METHODS & MATERIALS

A. Yeast Strains, Media and Plasmids
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Yeast strains were grown in yeast complete media containing 1% raffinose, transformed with 1μg of each plasmids containing ribosomal genes and plated on synthetic defined medium lacking uracil along with 1% raffinose. The transformants were selected and streaked for single colonies and three single colonies were selected for serial dilution and titration spottingin synthetic media containing either 2% glucose (repression) or 2% galactose (induction).The wild-type strain containing Htt25Q when overexpressed in presence of galactose,can grow normally whereasthe mutant htt strain having Htt103Q should die or show reduced growth in presence of galactose as illustrated in Fig 1. We selected theribosomal genesfor their ability to grow on plates containing galactose as suppressors of the Htt103Q toxicity.
IV. RESULTS AND DISCUSSIONS
A. Identification of Ribosomal Genes that Suppressed Htt103Q Toxicity
We overexpressed 243 MORF plasmids containing ribosomal genesin the Htt25Q and Htt103Q yeast strains individually and screened each strain at least in duplicate for the ability to suppress Htt103Q toxicity under conditions in which the genes are expressed strongly under agalactose-inducible promoter (i.e., when grown on media containing galactose and raffinose, but no glucose). Both the yeast strains were transformed with negative control (BG, vector alone), ribosomal MORF plasmids followed by titration spotting of selected transformantsin presence and absence of galactose (Fig 2) . By these assays, we confirmed 41 ribosomal genes(out of a total of 243 ribosomal MORF genes) that displayed successful suppression of cellular toxicity under conditions wherein the genes were transcriptionally induced to high levels by galactose induction but not otherwise. Table I lists these suppressor genes (a complete list of the genes tested for suppression is provided in Appendix A). We subsequently searched for the human homologs of the 41 suppressor genes, and found a total of 22 human homologs corresponding to these genes using the Stanford Saccharomyces cerevisiae Genome Database (SGD) [9] . The human homologs of the corresponding yeast suppressor genes are also listed in Table I .
B. Understanding Mechanism using Network Analysis
We constructed a network model for our 22 human homologous genes corresponding to the 41 ribosomal suppressors of mutant htt toxicity by mapping their physical and genetic interactions using the GENEMANIA integrated network web resource [10] . The interactome of the 22 human genes was generated by determining at most 50 first-degree neighbors of the 22 query gene nodes that produced a completely connected network. Only experimentally validated protein-protein physical interaction data and genetic interaction data were admitted into the interactome search space. Fig. 3 shows the network model.The gene nodes had manymore physical than genetic interactions,which was expected because these MORFs were specifically select-edfor their functions in protein biogenesis and ribosome, which are known to have many physical interactions. ). Network was constructed by querying GENEMANIA [10] (accessed August 4, 2013) This network, in addition to being enriched for ribosome function-obvious because the query genes encoded ribosomal proteins-is also enriched for protein targeting to endoplasmic reticulum and cellular membranes, and mRNA degradation (e.g., nonsensemediated decay) processes (See legend to Fig. 3) . It was previously noted that Htt toxicity causes defective membrane translocation of certain proteins [11] . However, the link to mRNA degradation appears to be novel.This novel observation allows us to make the hypothesis that Htt103Q toxicity might actually mediate selective degradation of certain mRNA molecules in the diseased neural cells. Indeed, Htt has been found to associate with RNA P-granules, which are found in certain neurons and are important for selective mRNA degradation and/or release in neural cells [12] . Our observation that the network of Htt103Q suppressors is enriched for mRNA degradation genes provides a novel functional genetic link between Htttoxicity and mRNA degradation.
APPENDIXA
The complete list of ribosomal genes of S. cerevisiaescreened in this work for suppression of toxicity by Htt103Q can be found at: https://docs.google.com/spreadsheet/ccc?key=0AmgeRH gAeZiHdDNnR1FNeTVCTXZMX05fMTRzeC1RX1E& usp=sharing
